机译:Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
Hematology Unit;
Department of Hemato‐Oncology and Radiotherapy,Hematology Unit;
Unit of Hematology and Stem Cell TransplantationDepartment of Medicine,Section of HematologyHematology Unit and Pathology Department,S. Eugenio Hospital RomeHematologyDepartment of Hemato‐Oncology and Radiotherapy,Stem Cell Transplantation UnitInstitute of Haematology and Stem Cell TransplantationComplex Operative Unit of HematologyNephrology Center of National Research Institute of Biomedicine and Molecular ImmunologyUOC Ematologia a Indirizzo OncologicoDepartment of Experimental and Clinical Medicine,University “Magna Graecia” of CatanzaroDivision of HematologySeràgnoli Institute of Hematology and Medical OncologyIstituto di EmatologiaDepartment of Medical and Surgical Specialties,Hematology SectionDepartment of Cellular Biotechnologies and Hematology,Sapienza University of RomeDepartment of Hematology,Businco HospitalScientific Directorate Azienda USL‐IRCCS of Reggio EmiliaHemato‐Oncology DepartmentHematology and Bone Marrow Transplant UnitOnco‐hematology UnitDepartment of Hematology‐Oncology,Hematology DivisionOnco‐hematology Unit Azienda Ospedaliera Santa Maria of TerniInternal Medicine, Ospedale S. CroceDepartment of Biomedical Science,University of Bari “Aldo Moro” Medical SchoolDepartment of Medicine,Hematology and Clinical Immunology SectionDepartment of Hematology,Hospital University RiunitiDepartment of Hematology and Bone Marrow Transplant,IRCCS Casa Sollievo della SofferenzaHematology Department;
dexamethasone; elotuzumab; lenalidomide; multiple myeloma; salvage therapy;